Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
Browsing: Pharma
Irish antibiotics specialist Itelm Therapeutics has begun winding down its operations, citing limited funds amid…
Biogen raises $5.6 billion for Apellis and its two approved drugs, aiming for rapid commercial tailwinds
By healthadmin
Despite a healthy roster of late-stage assets and a revenue recovery in 2025, it’s no…
Insulet has reinstated the chief commercial officer position nearly three years after eliminating the role…
Following high-profile moves by Eli Lilly and other major drug companies to pause investment in…
United plans to file an FDA application for Tivaso. With 3 wins, the topic of “New IPF Standards” is a big hit.
By healthadmin
With Tivaso’s second Phase 3 victory in idiopathic pulmonary fibrosis (IPF), United Therapeutics is inflating…
Idorsia focuses on use in pediatric insomnia, scoring victory in mid-stage clinical trial for sleeping drug Quviviq
By healthadmin
Idorsia’s insomnia drug Kuvivik (dalidrexant) moves one step closer to becoming a first-in-class treatment for…
Takeda Pharmaceutical Co. has begun cutting jobs in the United States, aiming to cut costs…
Samsung Biologics Union gathers strike votes as tensions over wages and governance rise
By healthadmin
Booming Samsung Biologics is facing rare public turmoil after the CDMO’s union secured the votes…
Biogen looks to break free from SMA status quo after FDA agrees to high-dose version of Spinraza
By healthadmin
Since FDA approval of Spinraza nearly a decade ago, Biogen’s spinal muscular atrophy (SMA) treatment…
Navigating 2026 Pharma Trends: Challenges and Opportunities for Drug Development Leaders
By healthadmin
Pharmacologists, executives, and regulatory professionals face explosive growth in AI-powered drug discovery, biopharma manufacturing shifts, clinical pipelines, and FDA evolutions. Explore key trends and strategies for resilient growth.